Infectious, Autoimmune and Other Immune-Mediated Causes of Myelitis


Diseasea

Clinical presentation and diagnostic characteristics

Myelitis with autoimmune-/immunemediated CNS disorders

Multiple sclerosis (MS)

Relapsing or progressive, lesions typically short and laterally localised in the spinal cord, cranial MRI with signs of dissemination in time and space, typical CSF findings (pleocytosis, oligoclonal bands, intrathecal IgG production)

Neuromyelitis optica spectrum disorder (NMOSD)

Relapsing, lesions typically presenting as longitudinal extensive transverse myelitis (LETM) spanning over ≥3 vertebral segments, often centrally located, cranial MRI not typical for MS, serum anti-aquaporin-4 antibodies

Acute disseminated encephalomyelitis (ADEM)

Monophasic (multiphasic possible), associated with previous infections and vaccination, MRI with large lesions in the cerebral white and grey matter, often of the same age and gadolinium enhancing, no dissemination in time, CSF without oligoclonal bands

Idiopathic transverse myelitis

Monophasic, CSF pleocytosis, positive oligoclonal bands (often transient)

Paraneoplastic

Association with solid tumours or haematological neoplasms, often paraneoplastic antibodies

Para-/postinfectious

Monophasic, associated with previous infection, often brain involvement

Para-/post-vaccinal

Monophasic, associated with previous vaccination, can be accompanied by radiculitis and inflammatory polyneuropathy

Anti-TNFα agents

Association with anti-TNFα therapy for rheumatoid arthritis, demyelinating, can additionally affect brain and peripheral nervous system

Myelitis as complication of inflammatory multisystem disorders

Sarcoidosis

Often LETM, brain and cranial nerve involvement possible, pulmonary or lymph node manifestations (not always), soluble IL-2 receptor elevated in serum, definite diagnosis by biopsy

Sjögren’s syndrome

Dry eyes and reduced production of saliva (sicca syndrome), anti-SS-A antibodies, anti-SS-B antibodies

Systemic lupus erythematosus (SLE)

Neuropsychiatric complications, anti-nuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA) antibodies, antiphospholipid antibodies

Behçet’s disease

Recurring aphthous stomatitis, genital ulceration, uveitis and arthropathy

Mixed connective tissue disease (MCTD)

Rare, often affecting thoracic cord

Systemic sclerosis

Rare, transverse myelopathy

Vasculitis

Rare, necrotising myelopathy


aOrder from highest to lowest prevalence



The clinical features of autoimmune and immune-mediated myelitis are mainly defined by the anatomic location and extent of injury to the spinal cord in its craniocaudal and transverse axes, to a lesser degree by the immune mechanisms involved. Apart from Sjögren’s syndrome and para-/postinfectious, paraneoplastic and para-/post-vaccinal aetiologies, which can all present with concomitant radiculitis and cause flaccid paresis, weakness is usually of the upper motor neuron type with associated spasticity, exaggerated reflexes and extensor plantar reflexes.



6.1.2 Multiple Sclerosis


Multiple sclerosis (MS) is the most common autoimmune demyelinating disease of the central nervous system (CNS), showing a female preponderance [35]. MS can take a relapsing–remitting or a primary or secondary progressive disease course, the latter with or without active inflammation [111]. A primary manifestation or relapses of MS as myelitis is common and is the most frequent cause of autoimmune myelitis. In individuals with known MS, a new spinal manifestation should therefore primarily be diagnosed and treated as an MS relapse. Spinal cord lesions in MS are typically short, spanning over one or two segments, and localised laterally in the spinal cord (Fig. 6.1). Contrast enhancement is seen regularly in acute lesions. A longitudinal myelitis is not typical for MS and should trigger alternative diagnoses such as neuromyelitis optica spectrum disorder (NMOSD, see below). Patients presenting with a monofocal myelitis and asymptomatic brain lesions without contrast enhancement have a high risk of developing a clinically definite MS in the future [138]. With at least two additional lesions in cranial MRI, one with contrast enhancement, the current diagnostic criteria allow the definite diagnosis of MS [141] and underline the importance of a cranial MRI in patients initially presenting with a clinically isolated myelitis. CSF examination reveals a mild pleocytosis, normally below 50 cells/μL with a predominance for activated lymphocytes. Oligoclonal bands and signs for a polyspecific intrathecal antibody production are found in the majority of MS patients and support the diagnosis. A thorough differential diagnosis should exclude other causes. Treatment of spinal manifestation of MS follows the general recommendations of relapse treatment including high-dose steroids and in the case of steroid-refractory functional deficits the use of apheresis therapies (see Sect. 6.1.11). Long-term treatment of MS is based on the use of immunomodulatory and immunosuppressive strategies.

A323639_1_En_6_Fig1_HTML.gif


Fig. 6.1
Multiple sclerosis (MS). Spinal MRI of a 23-year-old male presenting with subacute onset of right-sided hypaesthesia of the trunk. The patient was subsequently diagnosed with a relapsing–remitting MS. (a, b) Sagittal and (c, d) axial T2- and T1-weighted images show a monosegmental laterally located myelitis. (b, d) Gadolinium enhancement is shown. Arrows indicate the anterior spinal artery (Images courtesy of Dr. Peter Raab, Neuroradiology, Hannover Medical School)


6.1.3 Neuromyelitis Optica Spectrum Disorder


Neuromyelitis optica spectrum disorder (NMOSD) is a disabling autoimmune condition of the CNS characterised by inflammation predominantly of the optic nerves and the spinal cord. Neuromyelitis optica (NMO), also known as Devic’s disease, was long considered a variant of MS. However, the discovery of highly specific serum autoantibodies against aquaporin 4 (AQP4) in a subset (60–80 %) of patients with NMO has identified NMO as a distinct disease entity completely separate from MS [12, 22, 108, 196]. With characterisation of patients with AQP4 antibodies but not the full clinical picture of NMO, the spectrum of the disease entity has been expanded, and the term NMO spectrum disorder (NMOSD) was introduced [197]. In 2015, the diagnostic criteria of NMOSD were revised and underline the importance of the presence of AQP4 antibodies with stratifying NMOSD in those with and without AQP4 antibodies [198]. The core clinical characteristics required for patients with NMOSD with AQP4 antibodies include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema and other brainstem, diencephalic or cerebral presentations. More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4 antibodies or when serologic testing is unavailable.

Spinal cord affection in NMOSD patients shows typically an LETM, which is defined as spanning over at least three vertebral segments (Fig. 6.2). Lesions are often found centrally in the spinal cord. Contrast enhancement is patchy and long lasting. Recently, anti-MOG antibodies were detected in some AQP4 antibody-negative NMOSD patients, constituting approximately 5 % of all NMOSD patients [102, 112, 155]. NMOSD has a strong female preponderance (up to 10:1 depending on geographical region). The occurrence and frequency of myelitis in the first year predicts the long-term course of NMOSD [86]. Contrary to MS, myelitis in NMOSD often leaves residual deficits with complete remissions in only 20 % of cases. Since the outcome of NMOSD attacks is decisive for long-term disability, early escalation of attack treatment is recommended [103]. Apheresis therapies might be superior to high-dose corticosteroids for the first-line treatment of NMOSD myelitis [103]. Concomitant autoimmune or rheumatologic diseases occur in up to 40 % of patients with NMOSD [82]. LETM can also be found of other origin than in NMOSD; therefore, a thorough differential work-up is essential [186]. Long-term treatment of NMOSD is immunosuppressive; first-line therapies are azathioprine or rituximab [187].

A323639_1_En_6_Fig2_HTML.gif


Fig. 6.2
Neuromyelitis optica spectrum disorder (NMOSD). Spinal MRI of a 61-year-old woman with acute painful tetraparesis and aquaporin-4 antibody-positive NMOSD. (a) Sagittal T2-weighted and (b) axial T2-weighted images show a longitudinally extensive transverse myelitis (LETM) spanning five vertebral segments and the whole axial plane. Notice spinal oedema with swelling of the myelon. (c) Patchy, “cloud-like” gadolinium enhancement on T1-weighted sagittal image (Images courtesy of Prof. Carsten Lukas, Radiology, St. Josef Hospital Bochum)


6.1.4 Acute Disseminated Encephalomyelitis


Acute disseminated encephalomyelitis (ADEM) is a monophasic (multiphasic possible) inflammatory multifocal disease of the CNS [180]. ADEM typically affects children and young adults. An association with previous infections and vaccination has repeatedly been reported [149]. Clinical presentation ranges from a prodromal phase with fever, headache and nausea to the rapid appearance of multifocal neurological deficits, often accompanied by reduced consciousness and a psychosyndrome. Cranial MRI typically exhibits large lesions in the white and grey matter with perifocal oedema, often of the same age and gadolinium enhancing [203]. The involvement of the spinal cord is frequently observed, showing lesions of longitudinal extent [9]. ADEM is associated with occurrence of anti-MOG antibodies, particularly in children [11, 112].

Diagnosis is based on the combination of clinical presentation, cranial MRI with multifocal lesions of the same age, spinal MRI with longitudinal myelitis and CSF examination revealing mild to moderate pleocytosis and absence of oligoclonal bands. Therapy comprises of high-dose methylprednisolone but can also include therapeutic plasma exchange, intravenous immunoglobulins and immunosuppressants.


6.1.5 Idiopathic Transverse Myelitis


The diagnosis of an idiopathic transverse myelitis (ITM) is based on exclusion of other diseases. About 40 % of acute transverse myelopathies remain unexplained [163]. The “Transverse Myelitis Consortium Working Group” (TMCWG) has proposed diagnostic criteria for an idiopathic transverse myelitis [184]. Besides a typical clinical presentation for a spinal cord lesion, the diagnosis requires signs of an inflammatory aetiology either by MRI (hyperintensities in T2-weighted images, contrast enhancement) or in the CSF with a pleocytosis or intrathecal immunoglobulin production (elevated IgG index). Other aetiologies, particularly infectious or autoimmune disease, vascular or metabolic disease and hypovitaminosis, have to be excluded by a thorough differential diagnostic work-up.

ITM usually is monophasic and has a good outcome in the majority of patients [184]. About one third of patients initially diagnosed with an ITM and normal cranial MRI will develop a clinically definite MS within 5 years [138]. Recurring transverse myelitis without other CNS manifestation can occur in about 8 % of patients with an acute isolated ITM [166].


6.1.6 Myelitis with Systemic Autoimmune Diseases


Spinal cord affliction can occur as a complication of multisystem autoimmune or inflammatory disorders, for example, sarcoidosis, Sjögren’s disease, systemic lupus erythematosus (SLE), Behçet’s disease, mixed connective tissue disease, vasculitis and others.


6.1.6.1 Sarcoidosis


Sarcoidosis is a granulomatous disease of unknown aetiology which typically involves various organs with a predilection of the lungs (in about 90 % of patients) and lymph nodes [38, 89]. Clinical involvement of the CNS usually occurs early in the disease and is reported in approximately 5–15 % of cases [175]. Cranial neuropathy, papilloedema, aseptic meningitis, hydrocephalus, seizures, psychiatric symptoms, cerebral and also spinal lesions as well as peripheral neuropathy and skeletal muscle involvement have been described as neurological complications. Spinal lesions are typically longitudinally and centrally located in the cord (Fig. 6.3). Primary manifestation of a sarcoidosis as an LETM in the nervous system is possible [19]. Diagnostic work-up includes CSF analysis showing mild to moderate pleocytosis and mild disruption of the blood–brain barrier, serum soluble IL-2 receptor, chest imaging and whole body FDG-PET scan to identify hypermetabolic lymph nodes. Definite diagnosis of sarcoidosis still has to be inferred from biopsy. Therapy comprises of corticosteroids and immunosuppressants; in rapid progressive cases, successful treatment with infliximab has been reported [30, 88, 192].

A323639_1_En_6_Fig3_HTML.gif


Fig. 6.3
Neurosarcoidosis. MRI of the thoracic spinal cord of a 52-year-old woman with acute paraparesis and biopsy-proven pulmonary sarcoidosis. (a) Sagittal T2- and (b) fat-suppressed T1-weighted images after gadolinium injection show a longitudinally extensive lesion with enhancement of the dorsal column (Images courtesy of Prof. Carsten Lukas, Radiology, St. Josef Hospital Bochum)


6.1.6.2 Sjögren’s Syndrome


Sjögren’s syndrome is a systemic autoimmune disease that affects primarily the exocrine glands and is associated with anti-SSA (anti-Ro) and anti-SSB (anti-La) antibodies [194]. Typical symptoms are dry eyes and reduced production of saliva. Vasculitis and CNS involvement can be observed as typical and frequent extraglandular manifestations of primary Sjögren’s syndrome [48, 60]. A painful, mostly sensory polyneuropathy and sensory ganglionopathy are the most frequent neurological complications. CNS involvement shows a wide spectrum, occurs far less often and includes asymptomatic white matter lesions on MRI but also severe focal neurological symptoms including optic neuritis and transverse myelitis [48]. Myelitis often is longitudinal in extent and can affect all parts of the cord [14]. Overlap syndromes with NMOSD are frequently encountered; hence, testing for AQP4 antibodies is recommended [14, 85].


6.1.6.3 Systemic Lupus Erythematosus (SLE)


Neurological involvement in patients with SLE is frequent and ranges from mild neurocognitive dysfunction and mood changes to severe psychiatric and neurological manifestations such as seizures, stroke and psychosis [15]. Spinal cord involvement is less common (about 1–2 %) and mostly presents as transverse myelitis [105]. Myelitis with longitudinal extent has also been reported [76, 125]. Diagnostic work-up should include serological tests in search for anti-nuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA) antibodies and antiphospholipid antibodies. CSF analysis shows mild to moderate pleocytosis and mild disruption of the blood–brain barrier. Severity of neurological impairment during myelitis is a prognostic marker for long-term outcome [154]. Overlap syndromes with NMOSD are reported [154] and testing for AQP4 antibodies is recommended [85].


6.1.6.4 Behçet’s Disease


Behçet’s disease as another chronic, multisystem, inflammatory disorder is characterised by a small vessel vasculitis [24]. The clinical picture is dominated by recurring aphthous stomatitis, genital ulceration, uveitis and arthropathy [40]. Neurological manifestations commonly involve the basal ganglia and brainstem and occur in up to a third of the patients [2]. In approximately 10 % of Behçet cases with neurological manifestation, spinal cord involvement is reported. LETM can also be the sole presentation of neuro-Behçet’s disease [39]. Myelitis associated with Behçet’s disease often presents as longitudinally extensive [58, 190, 201]. Outcome of Behçet-associated myelitis is often poor. Early and aggressive immunosuppressive treatment is critical [98].


6.1.6.5 Mixed Connective Tissue Disease


Spinal cord affection in conjunction with mixed connective tissue (MCTD) disease is extremely rare, has only been reported in single case studies and often presents as transverse myelitis in the thoracic cord [16]. Neurological complications occur in about 10 % of patients with MCTD and are most commonly peripheral neuropathies, meningitis, psychosis and convulsions [126].


6.1.6.6 Systemic Sclerosis


Only few cases of myelitis associated with systemic sclerosis have been reported [110, 182]. Neurological complications of systemic sclerosis are uncommon and usually present as myopathy or neuropathy of cranial or peripheral nerves. Rarely, the CNS or spinal cord is afflicted, the latter as compressive (secondary to osteolysis, calcific deposits or facet arthropathy) or non-compressive transverse myelopathy [6, 110]. MRI, CSF and clinical evaluation support the diagnosis of myelitis, and immunosuppressive therapies are used for remission induction.


6.1.6.7 Vasculitis


The clinical presentation of spinal cord disease associated with vasculitis can range from mild myelitis to severe necrotising myelopathy. Most common causes are SLE, Behçet’s disease and Sjögren’s syndrome (see above). Single cases of myelitis in patients with pANCA-associated vasculitis [71], urticarial vasculitis [20] and immune-complex allergic vasculitis [129] have been described. In one 65-year-old man with systemic pANCA-associated vasculitis, MRI showed patchy cord enhancement from T10 to the conus, remitting after steroid therapy [71]. Usually pANCA-positive Wegener’s granulomatosis only affects the brain, meninges and cranial nerves.


6.1.6.8 Antiphospholipid Syndrome


The antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterised by presence of antiphospholipid antibodies, recurrent thrombosis and obstetrical morbidity. Neurological manifestations of APS are mainly thrombotic and include stroke, transient ischaemic attack, Sneddon’s syndrome, neuropsychological deficits and peripheral neuropathy [146]. In a systemic review covering the literature from 1966 to 2010, 14 cases of APS and simultaneous transverse myelitis were identified [147]. The causal relationship is unclear, particularly since a comorbidity of APS and NMOSD was reported [82, 121] and the presented cases remained untested for AQP4 antibodies.


6.1.7 Paraneoplastic Myelopathies


Myelopathies occurring in association with cancer are rare. Spinal cord paraneoplastic syndromes include inflammatory, necrotising or demyelinating myelitis, which may have a focal, transverse or longitudinally extensive dissemination [42]. Myelitis can be accompanied by motor neuron disease, subacute motor neuronopathy or stiff-person syndrome.

The diagnosis of a paraneoplastic myelitis is made by exclusion of other autoimmune or infectious causes of myelitis and CSF or imaging findings supporting acute inflammation, i.e. CSF pleocytosis and IgG index elevation, as well as gadolinium enhancement. Cancers and paraneoplastic antibodies commonly associated with myelitis include small cell lung carcinoma (anti-Hu, anti-Ri, anti-amphiphysin, anti-CRMP5/CV2, anti-GAD, P/Q and N type calcium channel antibodies), breast carcinoma (anti-PCA1, anti-amphiphysin) and ovarian cancer (anti-Ri) [84, 120]. Additionally, AQP4 antibodies are sometimes found positive, particularly in patients with breast carcinoma and in the elderly [130, 140]. Hence, LETM in the context of NMOSD can also represent a cancer-associated aetiology. Other cancers associated with AQP4 antibodies include lung, thymic and cervical carcinomas, leiomyosarcoma and lymphomas. Apart from cancers, demyelinating myelopathy was also described as a rare manifestation of graft-versus-host disease [63]. The paraneoplastic form of stiff-person syndrome occurs in 5–10 % of patients; is characterised by rapidly evolving pain, rigidity and stiffness; and is frequently associated with anti-amphiphysin, anti-GAD65 or anti-glycine receptor antibodies.

Paraneoplastic myelitis is often progressive and may lead to wheelchair dependency and death [57]. Acute paraneoplastic myelitis is treated with high-dose corticosteroids, intravenous immunoglobulins and therapeutic plasma exchange and stiff-person syndrome additionally with antispasticity drugs. Therapy of the underlying tumour is the most important long-term treatment; however, since relapses and progressive courses occur, additional immunosuppressive treatment is often needed.


6.1.8 Para-/Postinfectious Myelitis


Myelitis can be associated with concomitant or antecedent viral, rarely bacterial, infections [149]. Patients typically report an upper respiratory tract infection or a nonspecific febrile illness. Para-/postinfectious myelitis may present as isolated, mostly transverse myelitis, or together with a more widespread encephalomyelitis and can range from mild urinary symptoms from a conus/epiconus lesion [143] to severe ADEM and even involvement of the whole peripheral and central nervous system (“encephalomyeloradiculopathy”) [114]. An immune-mediated mechanism, i.e. bystander activation or molecular mimicry, is thought to be the pathogenic mechanism. Specific causes of para-/postinfectious myelitis are discussed under the individual pathogens involved. Typical are herpes viruses, orthomyxo- and paramyxoviruses (influenza, measles, mumps) and rubella virus. As with idiopathic transverse myelitis, diagnosis depends on spinal MRI, typically showing gadolinium enhancement and an inflammatory CSF with pleocytosis, abnormal IgG index and sometimes oligoclonal bands but absent pathogen or specific antibody index. Steroid pulse therapy and plasma exchange are used for remission induction, intravenous immunoglobulins in cases with contraindications for these therapies [172]. Since para-/postinfectious myelitis usually is monophasic, long-term immunosuppressive therapy is rarely needed.


6.1.9 Myelitis After Vaccination and as Complication of Immunotherapy


Neurological complications of vaccinations are rare [123]. LETM with local oedema and axonal motor neuropathy was described in a 77-year-old Japanese woman after vaccination against A/H1N1 influenza [156]. In a systematic review of PubMed, EMBASE and DynaMed, 37 cases of transverse myelitis associated with previous vaccinations were found for a period from 1970 to 2009 [1]. Cases were associated with vaccines against hepatitis B, measles–mumps–rubella, diphtheria–tetanus, rabies, poliovirus, influenza, typhus, pertussis and Japanese B encephalitis in decreasing order and typically occurred in the first month after vaccination.

Therapeutic inhibition of the tumour necrosis factor (TNF)-α is associated with CNS demyelination [46, 202]. In a review of 33 patients with neurological complaints which occurred within a median of 10 months after initiation of anti-TNFα agents, 22 had CNS involvement, 16 with encephalitic lesions, 5 with optic neuritis and 8 with transverse myelitis [169]. CSF and evoked potentials frequently are abnormal in patients with CNS involvement. Myelitis associated with anti-TNFα agents usually is monophasic, but relapsing episodes with final diagnosis of multiple sclerosis have been described. Consequently, anti-TNFα therapy should be discontinued when demyelinating myelitis occurs.

Both myelitis after vaccination and as complication of immunotherapy lack specific clinical and ancillary findings. It is discussed controversially whether the temporal association of vaccinations and anti-TNFα therapies with myelitis indicates a causal relationship, triggering of an underlying disease process, or occurs merely by chance.


6.1.10 Diagnostic Work-Up


Patients presenting with signs and symptoms of acute autoimmune or immune-mediated spinal cord affection should be immediately subjected to MRI of the complete spinal axis. First priority is to rule out a compressive aetiology [184]. The appearance and longitudinal extension of intramedullary lesions can guide diagnosis (Table 6.2). Further diagnostic testing (Table 6.3) should include CSF analysis, blood testing and cranial MRI, since most of these diseases can affect the brain as well [162]. A CSF pleocytosis with a cell count over 50 cells/μl should prompt the consideration of an infectious cause (see below), even though a high CSF cell count does not exclude an autoimmune inflammatory aetiology, particularly NMOSD, or even a neoplastic disorder. Additional blood testing aims to find systemic disorders such as SLE, Sjögren’s syndrome or sarcoidosis. A neurological involvement of these disorders should be considered in the setting of a positive serology and typical clinical presentation. The presence of a paraneoplastic antibody should prompt the search for the primary tumour using appropriate imaging techniques and a whole body FDG-PET scan where available. FDG-PET scanning can also be helpful to detect inflammatory lymph nodes in the setting of systemic sarcoidosis.


Table 6.2
Differential diagnosis of monosegmental versus longitudinal autoimmune myelitis

























Lesions typically <3 vertebral segments

Lesions typically ≥3 vertebral segments (LETM)

Multiple sclerosis

NMOSD

ITM

ADEM

Post-vaccinal myelitis

Paraneoplastic myelitis

Para-/postinfectious myelitis

Sarcoidosis

SLE

Behçet’s disease



Table 6.3
Diagnostic work-up for autoimmune myelitis




















Imaging

CSF analysis

Blood works

Spinal MRI:

Sagittal T2-TSE

Sagittal pre-/post-contrast T1 (slice thickness of 3 mm)

Axial T2-TSE

Axial post-contrast T1 (slice thickness of 4 mm or less)

Cell count and differentiation (lymphocyte, granulocyte, erythrocyte), cell cytology, protein, lactate, albumin quotient, immunoglobulin G/A/M quotient, antibody index for measles, rubella, varicella (MRZ reaction), oligoclonal IgG bands

Differential blood count, liver enzymes, serum creatinine, glomerular filtration rate, glucose, rheumatoid factor, anti-nuclear antibodies, ENA screening, anti-ds-DNA antibodies, c/pANCA, antiphospholipid antibodies, soluble IL-2 receptor, vitamin B12

Cranial MRI:

Axial T2-TSE/T2-FSE

Axial FLAIR

Axial T1-SE pre-/post-contrast and coronal T1w post-contrast

Sagittal T2-TSE/T2-FSE (3 mm slice thickness), centred medially

Optional:

Infectious agent screening

Optional:

AQP4 antibodies

MOG antibodies

Paraneoplastic antibodies

Serology for infectious agents


6.1.11 Therapeutic Strategies


With the exception of MS where additionally immunomodulatory therapies are used, treatment of spinal cord manifestations of autoimmune disorders is immunosuppressive. For acute attacks, high-dose methylprednisolone pulses are first line, sometimes to be followed by therapeutic plasma exchange, immunoadsorption or intravenous immunoglobulins (Table 6.4). When no complete recovery is achieved, immunosuppressive therapy, e.g. with rituximab, cyclophosphamide or mitoxantrone may be used for further remission induction. In the majority of autoimmune spinal cord diseases, the risk of a relapsing course is given; therefore, long-term treatment is required.


Table 6.4
Common therapies for acute autoimmune myelitis


































Therapy

Regimen

Route

Comments

Methylprednisolone

1 g for 3–5 days

IV

Rescue therapy with 3–5 × 2 g; oral tapering may be needed; regular pulses can be used for interval therapy

Plasma exchange

5–7 exchanges every other day

IV (central line)

Complications related to central line and plasma substitutes

Immunoadsorption

5–7 exchanges every other day

IV (central line)

Specific removal of plasma IgG, complications related to central line

Intravenous immunoglobulins (IVIG)

0.4 g/kg for 5 days

IV

Regular infusions can be used for interval therapy



6.2 Myelitis Caused by Pathogens



6.2.1 Introduction


Infections with viruses, bacteria, spirochaetales, fungi, protozoa or helminths can affect the spinal cord, nerve roots and adjacent structures, frequently resulting in severe long-term sequelae [13]. Herpes virus transverse myelitis and the tick-transmitted diseases neuroborreliosis and tick-borne encephalitis are the most common causes of infectious myelitis in Central Europe, whereas worldwide myelitis caused by enteroviridae (e.g. poliomyelitis or enterovirus) and spinal neurocysticercosis are more frequent. While most pathogens can cause acute myelitis, which represents a medical emergency, chronic myelitis or myelopathy with symptoms evolving over weeks or months is mostly restricted to retroviruses. Table 6.5 summarises the most common pathogens causing myelitis and their endemic regions.


Table 6.5
Pathogens causing myelitis and their endemic regions














































































Pathogen

Endemic region

Viruses

Herpes family viruses (herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein–Barr virus, human herpes viruses 6 and 7)

Worldwide

Flaviviruses (dengue virus, West Nile virus, tick-borne encephalitis virus, Japanese encephalitis virus, hepatitis C virus)

Dengue virus: Central and South America, sub-Saharan Africa, India, Southeast Asia, Pacific

West Nile virus: North America, Europe, Russia, sub-Saharan Africa, Australia, New Zealand, Pacific

Tick-borne encephalitis virus: Central Europe, Southeastern Europe, Baltic countries, southern Scandinavia, Russia, China, Korean peninsula

Japanese encephalitis virus: East and Southeast Asia

Hepatitis C virus: worldwide

Human immunodeficiency virus

Worldwide

Human T-cell lymphotropic virus

Japan, sub-Saharan Africa, Middle East, Caribbean, Central and South America

Picornaviruses (Coxsackie-, entero-, echoviruses, poliomyelitis virus, hepatitis A virus)

Coxsackie-, entero- and echoviruses, hepatitis A virus: worldwide

Poliomyelitis virus: Africa, Middle East

Hepadnaviruses (hepatitis B virus)

Worldwide

Bacteria and spirochaetales

Mycobacteria

Worldwide

Borrelia burgdorferi

Europe, North America, parts of Asia

Treponema pallidum

Worldwide

Staphylococcus, Streptococcus

Worldwide

Listeria

Worldwide (non-pasteurised milk products)

Mycoplasma

Worldwide

Chlamydophila spp.

Worldwide

Parasites

Schistosoma spp.

Schistosoma mansoni: Central and South America, sub-Saharan Africa

Schistosoma haematobium: sub-Saharan Africa

Schistosoma japonicum: Southeast Asia

Taenia solium (larval stage: cysticercus cellulosae)

Central and South America, sub-Saharan Africa, South and Southeast Asia

Echinococcus granulosus

Gnathostoma spinigerum

Toxocara spp.

Middle East, South America, New Zealand

Southeast Asia

Worldwide

Fungi

Moulds, in particular Aspergillus spp.

Worldwide

Yeasts

Worldwide

Blastomyces dermatitidis

North America

Coccidioides immitis

United States (southwest), Mexico, Central and South America


Adapted from Trebst et al. [187]


6.2.2 Herpes Family Viruses


Members of the herpes family viruses are capable of invading the CNS and infect particularly neurons. They establish a latent and life-long persisting infection in the dorsal root ganglia (review in [174]). These viruses can cause myelitis by primary infection and/or reactivation and probable spread to the spinal cord [81].


6.2.2.1 Herpes Simplex Virus


Herpes simplex virus (HSV) type 1 is the most common cause of infectious myelitis. HSV-1 myelitis can be subacute or chronic and mostly presents as monosegmental myelitis. Predisposing factors are diabetes mellitus, malignancies and conditions compromising the immune system, for example, immunosuppressive therapy or HIV infection. Nevertheless, not always an underlying condition can be found in individuals with herpes myelitis. Diagnostic work-up should particularly involve analysis of cerebrospinal fluid, normally exhibiting a mild pleocytosis (between 10 and 200 cells/μL) and mild disruption of the blood–brain barrier. Detection of viral DNA by polymerase chain reaction (PCR) in the CSF is the most important diagnostic step and helps to identify the causative agent. Importantly, PCR analysis can be negative for the first days after reactivation/infection. Therefore, the repeated analysis of the humoral immune response in the CSF can be helpful. The appearance of a positive CSF/serum antigen-specific index (ASI) is projected after 7 days of infection. Therapy includes high-dose aciclovir (10 mg/kg body weight IV, three times a day) for at least 14 days. Outcomes are variable; complete recovery is possible. Reoccurrence has been reported in up to 20 % of cases [31].


6.2.2.2 Varicella Zoster Virus


Reactivation of varicella zoster virus (VZV) normally involves a single or more dermatomes and can be accompanied or followed by myelitis (Fig. 6.4). Myelitis can also occur during primary infection. Diagnosis is supported by PCR and antibody analysis in the CSF. Therapy is the same as for HSV myelitis.

A323639_1_En_6_Fig4_HTML.gif


Fig. 6.4
VZV myelitis. (a, b) Herpes zoster skin lesion in a 70-year-old man presenting with paraparesis, urinary incontinence and sensory level Th7. T1-weighted (c) sagittal and (d) axial images of the thoracic spinal cord showing a well-demarked focal intramedullary lesion with gadolinium enhancement (Images courtesy of Prof. Erich Schmutzhard, Neurology, and Prof. Elke Gizewski, Neuroradiology, Innsbruck Medical University)


6.2.2.3 Cytomegalovirus


Cytomegalovirus (CMV) infection/reactivation is particularly observed in immunocompromised individuals. CMV can cause a lumbosacral polyradiculomyelitis and also an LETM [167]. CSF examination reveals a mild to moderate pleocytosis and mild disruption of the blood–brain barrier. Diagnosis is assured by positive PCR amplification of CMV-DNA in the CSF. CMV infection/reactivation can also be monitored by analysis of pp65 antigen levels in peripheral blood samples, particularly in bone marrow transplant recipients [65, 178]. Therapy involves ganciclovir and foscarnet. Prognosis is poor.


6.2.2.4 Epstein–Barr Virus


Epstein–Barr virus (EBV) is the causative agent of mononucleosis and therefore mostly found in children and young adults. Initial infection can be followed after weeks with signs of a polyradiculomyelopathy. This is most often a postinfectious immune-mediated syndrome, and patients respond well to steroid therapy, which is often given in combination with aciclovir.


6.2.2.5 Human Herpes Virus


Very rarely, human herpes virus (HHV)-6 and HHV-7 may be the causative agent of myelitis, in particular, as a complication after bone marrow transplantation [4, 195].


6.2.3 Flaviviruses


Flaviviruses are transmitted by arthropods (ticks, mosquitoes) and have either no (dengue viruses) or well-defined mammalian (tick-borne encephalitis viruses, Japanese encephalitis virus) and/or avian (West Nile virus) hosts. They are subsumed under the term arboviruses, i.e. arthropod-borne viruses. They cause either meningitis, encephalitis with special predilection for basal ganglia, or myelitis in which case they clearly show a predilection of the grey matter, i.e. of the anterior horns, causing a syndrome similar to poliomyelitis [75, 148].


6.2.3.1 Dengue Viruses


Dengue fever is a common arboviral infection in tropical and subtropical areas. Manifestations are increasingly recognised, but the exact incidence is still unknown [99, 193].

Dengue viruses are transmitted to humans by the bites of infective female Aedes mosquitoes (A. aegypti, A. albopictus, A. scutellaris, A. polynesiensis) with distinct peculiarities in ecology, behaviour and geographical distribution [49]. Infected humans are the primary reservoir, thus serving as the principal source of the virus for uninfected mosquitoes. However, although uncommon, vertical transmission from mother to foetus, transfusion-related transmission, transplantation-related transmission and needle stick-related transmission have been reported.

The clinical manifestations of dengue fever ranges from an asymptomatic state to severe dengue and dengue haemorrhagic shock syndrome, caused by inflammation, capillary leakage and multiorgan impairment. Encephalitis and meningitis are the most frequent CNS manifestations [77]; rarely dengue viruses may cause myelitis, mainly poliomyelitis [5].

Dengue virus-related myelitis presents in MRI as diffuse signal intensity alterations in the spinal cord. Since – as other flaviviridae – dengue viruses mainly affect the grey matter of the spinal cord, particularly anterior horn cells, the acute clinical presentation is flaccid para- or tetraparesis, eventually evolving into spastic para- or tetraparesis [44]. In these cases, myelitis is probably caused by direct viral invasion, as indicated by intrathecal synthesis of dengue IgG antibodies [122, 144]. Diagnosis is confirmed by detection of the virus, viral nucleic acid, antigen or antibodies in the CSF. The level of suspicion is increased by the presence of other laboratory abnormalities as thrombocytopenia, progressive leucopenia and clinical signs of capillary leakage syndrome.

Dengue viral infections of the CNS are managed symptomatically; careful monitoring and maintenance of fluid and electrolyte balance is essential, aggressive management of fever may contribute to success as a neuroprotective measure. Non-steroidal anti-inflammatory agents should not be prescribed since they may aggravate the bleeding diathesis [69].


6.2.3.2 Tick-Borne Encephalitis Viruses


Up to 30,000 cases of tick-borne encephalitis (TBE) are estimated to occur annually in the European and Asian northern hemisphere [79], thus rendering TBE to the most important and most frequent zoonotic arboviral infection in this region [3]. In nature, TBE virus (TBEV) cycles between infected ticks and small mammals, mainly rodents. Transstadial and transovarial transmission of the virus occur. Beside tick bites, alimentary routes of TBEV transmission – by consuming raw milk or milk products, mainly of goats – are seen.

There are three viral subtypes, the Central European TBEV, the Eastern European subtype and the Siberian/Eastern subtype, the latter two are usually transmitted by Ixodes persulcatus, whereas Ixodes ricinus is the major vector of the Central European TBEV subtype. After the infective tick bite, the virus multiplies at the site of inoculation; dendritic cells of the skin transmit the virus to local lymph nodes from where infected lymphocytes initiate the systemic spread of the infection. Infection of the CNS can occur everywhere, however, most frequently and most intensely involving brainstem, cerebellum, basal ganglia, thalami and spinal cord, where mainly anterior horn cells are infected [18]. Typically, the disease runs a biphasic course; the majority of TBEV infections, however, remain asymptomatic. After an incubation period of 2–28 days, the first stage, i.e. viraemic phase, presents with fever, muscle pains and fatigue. After an afebrile period of several days, the second phase starts mainly with meningitis, encephalitis (in older patients) and in up to 5–15 % with myelitis, most frequently presenting as poliomyelitis with flaccid paresis of the upper limbs [157].

No specific antiviral therapy exists; supportive measurements are most important to assure initial survival in patients with brainstem and encephalomyelitic involvement. CSF and MRI show unspecific changes; the diagnosis is confirmed by specific intrathecal antibody production [177]. Case fatality rate in tick-borne encephalitis depends on the initial clinical presentation being worst in the encephalitic and myelitic form. In Central European TBE, fatality rates are low (<2 %) [92], whereas in Siberian and far Eastern subtypes, fatality rates of >10 % have been reported.

In addition, long-term sequelae after TBE have been reported in 40–50 % in Western [92] and >60 % of patients in far Eastern and Siberian subtypes of disease [92, 177], and only 20 % of patients with TBE myelitis fully recover [91]. Active vaccination is recommended for TBEV-exposed persons in endemic regions.


6.2.3.3 West Nile Virus


West Nile virus (WNV) has first been described in Eastern Africa (West Nile province in Uganda) from where it has spread throughout the Eastern sub-Saharan African countries, towards Middle East countries, Balkan and, since around 15 years, towards the United States and Canada [68, 133, 164, 165]. Within the past 5 years, South European countries, in particular, Greece and Italy, and most recently even Central European Countries (e.g. Hungary, Italy, Austria) have reported autochthonous cases; [33]. The specific peculiarity of WNV infection is the transmission by mosquitoes, thus rendering WNV to the single most important mosquito-borne disease in temperate climates, e.g. the United States and Central Europe. The course of disease is very similar to TBE; however, in elderly and older subjects, a severe course of WNV neuroinvasive disease, i.e. encephalitis and myelitis, is seen more frequently. As in TBE, the myelitic course of WNV infection is predominated by affection of the anterior horn cells, thereby causing the clinical entity of a poliomyelitis type of disease [107, 113]. The presence of an intrathecal specific antibody production confirms the diagnosis of WNV neuroinvasive disease [45]. Management is supportive and includes all intensive care measures, when necessary [142]. In contrast to TBE, there is no protective vaccine available yet.


6.2.3.4 Japanese Encephalitis


Japanese encephalitis (JE) occurs in Asian countries ranging from Southeast China towards the Southeast and South Asian countries, including Nepal, India and small pouches in Pakistan. JE virus is transmitted by anopheles mosquitoes; the course is biphasic and frequently leads to encephalitis and also myelitis, where – similar to the other above-mentioned arboviral infections – the anterior horn cells are predominantly affected, thus causing a poliomyelitic course of disease. If the CNS is affected in JE, which occurs in <10 % of cases, the course of disease is much more severe than in TBE or even in WNV encephalitis/myelitis. Case fatality rates of >30 % have been reported [179]. Diagnostic and supportive management strategies are similar to other viral encephalitis and myelitis [90]. A highly efficacious active vaccine exists; travellers to endemic areas, mainly during rainy season, when the mosquito activity is highest, are advised to get this protective vaccination, in particular, if they plan to stay for more than 4 weeks in this endemic area.


6.2.4 Retroviruses



6.2.4.1 Human Immunodeficiency Virus


The human immunodeficiency virus (HIV) is a ubiquitously occurring retrovirus accounting for a total of about 37 million infected individuals worldwide (http://​www.​who.​int/​gho/​hiv/​en/​ of October 10th, 2016). Already during early infection, HIV can find its way into the CNS and cause an acute transverse myelitis. This is often categorised as an immune-mediated phenomenon and shows a good response to high-dose steroids and the start of antiretroviral therapy [70]. During further course of the disease, more chronic changes in the CNS are observed, particularly as encephalopathies but also as myelopathies. These are often characterised as slowly progressing gait disturbances and have to be distinguished from HIV- or antiretroviral therapy-associated neuropathies. Spinal MRI not always shows abnormalities, sometime only subtle changes of a beginning spinal atrophy or diffuse hyperintensities in the FLAIR and T2-weighted images with longitudinal extent and often restriction to the lateral and posterior thoracic cord [32] (Fig. 6.5). Diagnostic work-up should include exclusion of other infectious causes. Besides antiretroviral therapy regimes, no specific therapy applies for HIV myelopathy.
Aug 25, 2017 | Posted by in NEUROLOGY | Comments Off on Infectious, Autoimmune and Other Immune-Mediated Causes of Myelitis

Full access? Get Clinical Tree

Get Clinical Tree app for offline access